Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’

What: Enliven Therapeutics (ELVN) stock has reached a 5-year high.
Why: Analysts are optimistic about the company's prospects, citing positive developments in its pipeline.
Signal: The stock's surge indicates growing investor confidence in ELVN's potential for growth.
Target: Investors are likely to target a price range of **$25** to **$35** as the stock continues to rise.
Risk: A potential risk for investors is a correction in the market, which could impact ELVN's stock price.